ARTICLE | Company News

MorphoSys sales and marketing update

April 2, 2012 7:00 AM UTC

MorphoSys' AbD Serotec division launched six HuCAL anti-idiotypic antibodies worldwide to measure Herceptin trastuzumab levels in serum. AbD Serotec said the antibodies could be used in patient monitoring and preclinical research. The antibodies are available as high affinity monovalent Fab antibodies, ultra-high affinity monovalent Fab antibodies and human IgG1 antibodies for immunogenicity assays. ...